Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RLF-OD032
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed
Details : RLF-OD032 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2025
Lead Product(s) : RLF-OD032
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RLF-OD032
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects
Details : RLF-OD032 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2024
Lead Product(s) : RLF-OD032
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PKU Golike
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PKU Golike is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Phenylketonurias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : PKU Golike
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PKU Golike
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PKU Golike is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Phenylketonurias.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : PKU Golike
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19
Details : Aviptadil Acetate is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
November 30, 2021
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amino Acids Mixture,Minerals,Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Relief Therapeutics
Deal Size : $72.2 million
Deal Type : Acquisition
Details : Acquisition further diversifies Relief's pipeline with both commercial products and clinical-stage programs and provides a commercial infrastructure foundation for future product launches.
Product Name : PKU Golike
Product Type : Miscellaneous
Upfront Cash : $23.3 million
June 29, 2021
Lead Product(s) : Amino Acids Mixture,Minerals,Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Relief Therapeutics
Deal Size : $72.2 million
Deal Type : Acquisition
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)
Details : Aviptadil Acetate is a Peptide drug candidate, which is currently being evaluated in clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 01, 2020
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Inhaled ZYESAMIâ„¢ (Aviptadil Acetate) for the Treatment of Severe COVID-19
Details : Aviptadil Acetate is a Peptide drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
April 24, 2020
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : APR-OD031
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Orphan Drug Designation to APR-OD031 for the Treatment of Phenylketonuria (PKU)
Details : First mix of amino acids having a pharmacological primary mode of action designed to reduce and control Phenylalanine fluctuations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 26, 2020
Lead Product(s) : APR-OD031
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure
Details : Aviptadil is a Protein drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable